| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10741-017-9648-X |
| P698 | PubMed publication ID | 28856513 |
| P50 | author | Eric H. Yang | Q40261287 |
| P2093 | author name string | Eugene C DePasquale | |
| Arnold S Baas | |||
| Daniel J Philipson | |||
| P2860 | cites work | Altered high-energy phosphate metabolism predicts contractile dysfunction and subsequent ventricular remodeling in pressure-overload hypertrophy mice | Q80237124 |
| Not all systolic velocities indicate obstruction in hypertrophic cardiomyopathy: a simultaneous Doppler catheterization study | Q80446222 | ||
| Hypertrophic cardiomyopathy-related beta-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells | Q81023395 | ||
| Percutaneous Radiofrequency Septal Reduction for Hypertrophic Obstructive Cardiomyopathy in Children | Q82766072 | ||
| Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months' follow-up in 19 patients | Q83312124 | ||
| Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy | Q84433356 | ||
| Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction | Q84910660 | ||
| Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy | Q86421874 | ||
| Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME) | Q88546545 | ||
| Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis | Q24291256 | ||
| Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence | Q26991690 | ||
| Targets for therapy in sarcomeric cardiomyopathies | Q27027023 | ||
| Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes | Q28247074 | ||
| Ranolazine Improves Cardiac Diastolic Dysfunction Through Modulation of Myofilament Calcium Sensitivity | Q28260201 | ||
| Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy | Q28348531 | ||
| Cardiac hypertrophy: the good, the bad, and the ugly | Q29615247 | ||
| Update on hypertrophic cardiomyopathy and a guide to the guidelines. | Q30245043 | ||
| Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. | Q30457109 | ||
| Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. | Q30484558 | ||
| Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy | Q33148488 | ||
| Hypertrophic obstructive cardiomyopathy | Q33167969 | ||
| Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: Clarification of pathophysiology and importance in intraoperative decision making | Q33220909 | ||
| Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy | Q33978845 | ||
| Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction | Q34000763 | ||
| Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults | Q34058337 | ||
| Decoding calcium signals involved in cardiac growth and function | Q34076156 | ||
| Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. | Q34162142 | ||
| American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the Euro | Q34275552 | ||
| The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model | Q34790975 | ||
| Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression | Q35070184 | ||
| Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion | Q35113389 | ||
| Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease | Q35376769 | ||
| The case for surgery in obstructive hypertrophic cardiomyopathy. | Q35948306 | ||
| N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy | Q36339491 | ||
| The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study | Q37024682 | ||
| Dynamics of left ventricular ejection in obstructive and nonobstructive hypertrophic cardiomyopathy | Q37026827 | ||
| Bioinformatics assessment of beta-myosin mutations reveals myosin's high sensitivity to mutations | Q37191627 | ||
| An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy | Q37271880 | ||
| Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms | Q37413082 | ||
| Cardiomyopathy: a systematic review of disease-causing mutations in myosin heavy chain 7 and their phenotypic manifestations | Q37623384 | ||
| Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. | Q37631139 | ||
| Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility. | Q37680390 | ||
| Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy | Q37695397 | ||
| Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases | Q37701056 | ||
| Mechanical and energetic consequences of HCM-causing mutations | Q37766181 | ||
| Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent | Q37909293 | ||
| Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy. | Q38031711 | ||
| Cardiomyopathy in a dish: using human inducible pluripotent stem cells to model inherited cardiomyopathies | Q38454536 | ||
| Percutaneous repair or surgery for mitral regurgitation | Q38475417 | ||
| A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy. | Q38603902 | ||
| Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population | Q38606791 | ||
| The Mitral Valve in Obstructive Hypertrophic Cardiomyopathy: A Test in Context | Q38808937 | ||
| Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. | Q38816364 | ||
| A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. | Q38872061 | ||
| Trans-aortic Alfieri stitch at the time of septal myectomy for hypertrophic obstructive cardiomyopathy | Q38892760 | ||
| Obstruction is unimportant in the pathophysiology of hypertrophic cardiomyopathy | Q38951500 | ||
| Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. | Q39178375 | ||
| Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy | Q39423902 | ||
| Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging | Q40220691 | ||
| Chordal geometry determines the shape and extent of systolic anterior mitral motion: in vitro studies | Q41304156 | ||
| A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy | Q41571656 | ||
| Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial | Q41657513 | ||
| Contractility parameters of human β-cardiac myosin with the hypertrophic cardiomyopathy mutation R403Q show loss of motor function. | Q42119619 | ||
| Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. | Q42870189 | ||
| 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation | Q43612383 | ||
| Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy | Q43741617 | ||
| Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy | Q44454565 | ||
| Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy | Q44580888 | ||
| Endocardial radiofrequency ablation of septal hypertrophy. A new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy | Q44977788 | ||
| Artificially induced endometrial cycles and establishment of pregnancies in the absence of ovaries | Q45291376 | ||
| Resection-plication-release for hypertrophic cardiomyopathy: clinical and echocardiographic follow-up. | Q45767563 | ||
| Lys184 deletion in troponin I impairs relaxation kinetics and induces hypercontractility in murine cardiac myofibrils. | Q46445601 | ||
| Left ventricular outflow tract gradient variability in hypertrophic cardiomyopathy | Q46694322 | ||
| Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy | Q46729039 | ||
| Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment | Q46814911 | ||
| Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy | Q46822465 | ||
| A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker | Q46832105 | ||
| Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy | Q46836532 | ||
| Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments | Q46954266 | ||
| Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy | Q47872580 | ||
| Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy | Q48747768 | ||
| Clinical course of hypertrophic cardiomyopathy with survival to advanced age. | Q52954578 | ||
| Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy | Q52983281 | ||
| Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound® technology to guide ablation | Q53293390 | ||
| Relation of functional and morphological changes in mitochondria to myocardial contractile and relaxation reserves in asymptomatic to mildly symptomatic patients with hypertrophic cardiomyopathy | Q53392996 | ||
| Why we need more septal myectomy surgeons: An emerging recognition. | Q53458271 | ||
| Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography | Q54299933 | ||
| Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy | Q57841401 | ||
| Epidemiology of Hypertrophic Cardiomyopathy–Related Death | Q57841451 | ||
| Faster cross-bridge detachment and increased tension cost in human hypertrophic cardiomyopathy with the R403Q MYH7 mutation | Q58087435 | ||
| Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations | Q58087460 | ||
| Assessment of Diastolic Function With Doppler Tissue Imaging to Predict Genotype in Preclinical Hypertrophic Cardiomyopathy | Q61897195 | ||
| Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant alpha-tropomyosins in adult cardiac myocytes | Q64381152 | ||
| Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics | Q69692766 | ||
| Pressure recovery distal to a stenosis: potential cause of gradient "overestimation" by Doppler echocardiography | Q69948990 | ||
| Patterns of systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: assessment by two-dimensional echocardiography | Q70799056 | ||
| Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics | Q71807489 | ||
| Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate | Q72285365 | ||
| Muscular subaortic stenosis. Initial left ventricular inflow tract pressure in the assessment of intraventricular pressure differences in man | Q72333554 | ||
| Ultrasound Localization of Left Ventricular Outflow Obstruction in Hypertrophic Obstructive Cardiomyopathy | Q72519917 | ||
| The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis | Q72881805 | ||
| Unobstructed thinking (and terminology) is called for in the understanding and management of hypertrophic cardiomyopathy | Q73199242 | ||
| Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy | Q73313263 | ||
| Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy | Q73682058 | ||
| IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS. I. A DESCRIPTION OF THE DISEASE BASED UPON AN ANALYSIS OF 64 PATIENTS | Q77053465 | ||
| Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: mismatch of posterior to anterior leaflet length and mobility | Q77302921 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 879-888 | |
| P577 | publication date | 2017-11-01 | |
| P1433 | published in | Heart Failure Reviews | Q2167497 |
| P1476 | title | Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy | |
| P478 | volume | 22 |
Search more.